AbbVie's flagship drug, Humira, experienced a 40% revenue decline following its loss of exclusivity. This massive revenue gap creates significant pressure on the company to accelerate growth in other products and find operational efficiencies.
Filing excerpt
Net revenues for Humira decreased 40% for the three months ended March 31, 2026 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-10qmarketShareLossGet every 10-Q signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/28585197-b3d4-42d1-b91e-1a89b2d5835f returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "28585197-b3d4-42d1-b91e-1a89b2d5835f",
"signal_type": "sec-10q",
"signal_subtype": "marketShareLoss",
"detected_at": "2026-05-12T09:24:57.857+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "AbbVie's flagship drug, Humira, experienced a 40% revenue decline following its loss of exclusivity. This massive revenue gap creates significant pressure on the company to accelerate growth in other products and find operational efficiencies.",
"metrics": {
"pct": -40,
"timeframe": "current_quarter",
"pct_context": "YoY decrease in Humira net revenues for the three months ended March 31, 2026"
},
"summary": "Humira revenue plummets 40% in Q1 due to direct biosimilar competition",
"excerpts": "Net revenues for Humira decreased 40% for the three months ended March 31, 2026 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/abbv-20260331.htm",
"filing_date": "2026-05-08",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "03/31",
"sales_relevance": "Urgency to improve",
"signal_category": "market"
}
}
curl https://signals.autobound.ai/v1/signals/28585197-b3d4-42d1-b91e-1a89b2d5835f \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.